CRISPR and CRISPR-associated (Cas) Genes Market Report Scope & Overview:

The CRISPR and CRISPR-associated (Cas) Genes Market was valued at USD 5.20 Billion in 2025 and is expected to reach USD 19.11 Billion by 2035, growing at a CAGR of 13.90% from 2026-2035.

The CRISPR and CRISPR-associated (Cas) Genes Market covers reagents, kits, libraries, and services built around CRISPR-Cas9 and related nuclease systems used for genome engineering, functional genomics, and therapeutic gene editing. Demand tracks expanding biomedical research funding, growing clinical pipelines for ex vivo and in vivo gene therapies, and rising adoption of base and prime editing platforms offering improved precision over first-generation nuclease systems. Academic, pharmaceutical, and contract research organizations continue to drive reagent and service demand, while delivery technology limitations and regulatory scrutiny of germline editing continue to shape commercialization timelines. Producers are increasingly investing in off-the-shelf guide RNA libraries and cell-line engineering services to capture higher-margin applications beyond traditional reagent sales.

⮞In July 2025, Integrated DNA Technologies (IDT) expanded its translational CRISPR portfolio with higher-purity guide RNA options, off-target analysis services, and additional solutions designed to support the progression of genome-editing research toward clinical development. The expansion strengthens the availability of specialized reagents and analytical services for therapeutic gene-editing programs.

U.S. CRISPR and CRISPR-associated (Cas) Genes Market Outlook:

The U.S. CRISPR and CRISPR-associated (Cas) Genes Market was valued at USD 2.05 Billion in 2025 and is expected to reach USD 7.08 Billion by 2035, growing at a CAGR of 13.20% from 2026-2035.

Demand across the United States is shaped by a mature biopharmaceutical research base, substantial federal and private funding for gene editing therapeutics, and a dense concentration of academic and contract research institutions pursuing genome engineering programs. Established reagent and service providers headquartered in the country continue to prioritize guide RNA synthesis, cell-line engineering, and screening services sold into biotechnology and pharmaceutical company pipelines. Expanding clinical-stage gene editing programs across hematology and cardiovascular indications are widening demand for CRISPR-Cas reagents and delivery-compatible formulation services supporting late-stage development.

⮞In May 2025, Children's Hospital of Philadelphia and Penn Medicine announced the successful treatment of an infant with a personalized CRISPR-based gene-editing therapy developed for CPS1 deficiency. The treatment used a patient-specific base editor delivered through lipid nanoparticles, demonstrating the potential of customized genome-editing approaches in rare genetic diseases.

By Component/Product Type, Products Dominates the CRISPR and CRISPR-associated (Cas) Genes Market and Services Grows Fastest

Products hold the dominant component share in 2025, reflecting sustained demand for CRISPR-Cas9 kits, reagents, guide RNA libraries, and nuclease proteins sold directly to academic and biopharmaceutical research laboratories conducting genome engineering experiments. Suppliers offering validated, ready-to-use reagent kits continue to capture the broadest base of repeat purchasing among researchers seeking consistent editing efficiency across cell lines and model organisms. Continued expansion of functional genomics screening programs across major consuming regions is reinforcing products as the component category commanding the largest share of total CRISPR and Cas gene market consumption tracked in this report.

Services are the fastest-growing component, as biopharmaceutical companies and academic laboratories increasingly outsource cell-line engineering, guide RNA design, and custom screening work to specialized contract research providers rather than building internal capability across multiple program types. Suppliers offering end-to-end gene editing service packages are positioned to capture growing demand from customers seeking to accelerate program timelines without expanding in-house genome engineering teams. Continued growth in outsourced screening and cell-line engineering demand is reinforcing services as the fastest-expanding component category tracked across this report and across several research applications.

By Application, Biomedical Dominates the CRISPR and CRISPR-associated (Cas) Genes Market and Agriculture Grows Fastest

Biomedical applications hold the dominant share in 2025, reflecting extensive use of CRISPR-Cas systems across genome engineering, disease model development, functional genomics, and therapeutic gene editing programs spanning hematology, oncology, and rare disease indications. Biopharmaceutical and academic researchers continue to represent the largest addressable base for reagent and service suppliers, supported by expanding clinical pipelines and sustained research funding across major consuming regions. Continued growth in therapeutic gene editing programs is reinforcing biomedical applications as the category commanding the broadest base of CRISPR and Cas gene market consumption tracked in this report.

Agriculture is the fastest-growing application, as crop developers increasingly apply CRISPR-Cas systems to trait engineering, disease resistance, and yield improvement programs across major row crop and specialty crop categories worldwide. Suppliers offering plant-optimized guide RNA and delivery systems are positioned to capture growing demand from agricultural biotechnology developers seeking to accelerate trait development timelines relative to conventional breeding approaches. Continued regulatory clarity around gene-edited crop classification is reinforcing agriculture as the fastest-expanding application category tracked across this report and across several crop types.

⮞In April 2026, Intellia Therapeutics reported positive Phase III results from its HAELO trial of lonvoguran ziclumeran, an investigational in vivo CRISPR gene-editing therapy for hereditary angioedema. The trial met its primary and key secondary endpoints, marking an important clinical milestone for the development of systemic CRISPR-based treatments.

By End User, Biotechnology & Pharmaceutical Companies Dominates the CRISPR and CRISPR-associated (Cas) Genes Market and Contract Research/Manufacturing Organizations Grows Fastest

Biotechnology and pharmaceutical companies hold the dominant end-user share in 2025, reflecting their position as the primary developers of CRISPR-based therapeutics and the largest institutional purchasers of reagents, guide RNA libraries, and screening services supporting drug discovery programs. Established biopharmaceutical companies continue to represent the deepest base of recurring reagent and service purchasing, supported by expanding clinical pipelines across multiple therapeutic areas. Continued growth in biopharmaceutical gene editing pipelines is reinforcing this end-user category as the segment commanding the broadest base of CRISPR and Cas gene market consumption tracked in this report.

Contract research and contract manufacturing organizations are the fastest-growing end-user category, as biopharmaceutical sponsors increasingly outsource cell-line engineering, process development, and manufacturing work to specialized providers rather than building internal gene editing manufacturing capability. Suppliers offering integrated contract development and manufacturing services tailored for cell and gene therapy programs are positioned to capture growing demand from sponsors seeking to accelerate clinical timelines. Continued growth in outsourced cell and gene therapy manufacturing demand is reinforcing this end-user category as the fastest-expanding segment tracked across this report.

⮞In February 2026, CRISPR Therapeutics reported that its CRISPR/Cas9-based therapy CASGEVY generated USD 116 million in revenue during 2025. The company also reported that 64 patients received CASGEVY infusions during the year, while 147 patients globally initiated the treatment process through their first cell collection, reflecting growing commercial adoption of CRISPR-based therapeutics.

By Technology, CRISPR-Cas9 Dominates the CRISPR and CRISPR-associated (Cas) Genes Market and Prime Editing Grows Fastest

CRISPR-Cas9 holds the dominant technology share in 2025, reflecting its established role as the most widely validated and broadly licensed gene editing platform across academic and commercial genome engineering applications. Suppliers offering Cas9 nuclease proteins, guide RNA libraries, and validated editing kits continue to capture the broadest base of researcher adoption, supported by over a decade of published validation data and established intellectual property licensing frameworks. Continued reliance on Cas9-based editing across functional genomics and therapeutic development programs is reinforcing this technology as the category commanding the broadest base of CRISPR and Cas gene market consumption tracked in this report.

Prime editing is the fastest-growing technology, as developers increasingly adopt search-and-replace editing approaches that avoid double-strand breaks and offer improved precision for correcting point mutations relevant to inherited disease indications across several therapeutic areas and program types. Suppliers offering prime editing-compatible reagents and licensing access to pegRNA design platforms are positioned to capture growing demand from developers pursuing next-generation precision editing programs. Continued clinical validation of prime editing approaches is reinforcing this technology as the fastest-expanding category tracked across this report.

⮞In July 2026, the U.S. FDA expanded the approval of CASGEVY to patients aged two years and older with sickle cell disease or transfusion-dependent beta-thalassemia. The therapy uses a patient's own stem cells edited with CRISPR/Cas9, extending the eligible treatment population for an approved CRISPR-based product.

Regional Analysis:

North America CRISPR and CRISPR-associated (Cas) Genes Market Insights

North America represented an estimated 44.80 % share in 2025, anchored by a dense concentration of biopharmaceutical companies, academic research institutions, and contract research organizations pursuing genome engineering and therapeutic gene editing programs across the United States. Established reagent and service providers headquartered in the country continue to prioritize guide RNA synthesis, cell-line engineering, and screening services sold into biotechnology and pharmaceutical company pipelines. Continued expansion of clinical-stage gene editing programs is widening demand for CRISPR-Cas reagents and delivery-compatible formulation services supporting late-stage development across multiple therapeutic areas.

Canada contributes a smaller but steady share of regional demand, tied to academic genome engineering research and a growing base of biotechnology companies pursuing cell and gene therapy development across several provinces. Mexico remains a comparatively modest market, with demand concentrated among academic institutions and contract research providers serving cross-border biopharmaceutical development activity. Continued growth in North American biopharmaceutical funding and clinical pipeline expansion is reinforcing demand for reagent and service packages validated to consistent performance specifications across multiple research applications and institutions.

Asia Pacific CRISPR and CRISPR-associated (Cas) Genes Market Insights

Asia Pacific represented an estimated 22.90 % share in 2025 and is growing at a CAGR of approximately 17.20 % from 2026-2035, anchored by expanding biopharmaceutical research funding and a growing base of contract research organizations across China, Japan, and South Korea. Producers across the region continue to capture a growing share of reagent and service demand, supported by government-backed genomics research initiatives and expanding academic genome engineering programs. Continued growth in biopharmaceutical outsourcing activity across China and India is reinforcing Asia Pacific's position as a rapidly expanding region tracked in this report.

China’s expanding biopharmaceutical and contract research base continues to support regional demand, while Japan’s mature genomics research infrastructure supports steady reagent and service purchases across academic and commercial laboratories. Increasing government investment in genomics and precision medicine research programs across the region is maintaining high funding availability for genome engineering programs, expanding the addressable market for reagent and service suppliers. Ongoing growth in biopharmaceutical outsourcing and academic research funding throughout South Korea and India is further strengthening the regional demand outside of the conventional reagent-purchasing base that traditionally underpinned the region’s position.

⮞In July 2026, China's National Medical Products Administration granted IND clearance to GenEditBio's GEB-101, an investigational in vivo CRISPR-based gene-editing therapy for TGFBI-related corneal dystrophies. The clearance enables the company to initiate a Phase I/II clinical study in China, supporting the expansion of regional clinical development activity in genome editing.

Europe CRISPR and CRISPR-associated (Cas) Genes Market Insights

Europe represented an estimated 23.60 % share in 2025, supported by established academic genome engineering research institutions and a mature base of biopharmaceutical companies pursuing cell and gene therapy development across major consuming countries. Several reagent and service suppliers headquartered in the region continue to prioritize guide RNA synthesis and screening service chemistries validated for both academic and commercial genome engineering applications. Rising biopharmaceutical research funding across Germany, France, and the United Kingdom continues to widen demand for reagent and service packages supporting expanding clinical pipelines.

Regulatory caution around germline and heritable gene editing continues to shape commercialization timelines across the region, even as somatic cell therapeutic programs continue to advance through clinical development. Regional producers continue to pursue specialty reagent and screening service chemistries leveraging established academic and regulatory expertise, reinforcing Europe's position as both a research center and a steady reagent end-market in its own right. Competition from lower-cost Asian reagent suppliers continues to pressure regional pricing across several commodity-grade kit and reagent categories.

⮞In October 2026, Charité – Universitätsmedizin Berlin reported that it had treated the first patient in Germany with exagamglogene autotemcel, a CRISPR-based therapy for beta-thalassemia. The treatment was administered in May 2026 and marked the first use of this approved CRISPR-based therapy in Germany as part of standard medical care.

MEA & Latin America CRISPR and CRISPR-associated (Cas) Genes Market Insights

The Middle East and Africa represented an estimated 3.30 % share in 2025, with demand concentrated among a smaller number of academic and biopharmaceutical research institutions given the region's comparatively limited genome engineering research infrastructure and reliance on imported reagent and service offerings from established suppliers elsewhere. Continued investment in biomedical research capacity across the Gulf Cooperation Council countries is supporting steady demand for reagent kits and screening services, while broader regional consumption remains more limited than in established research markets elsewhere in this report.

Latin America accounts for 5.40% of the market in 2025 and is growing at a CAGR of around 15.80% during 2026-2035. Brazil is the largest national market in the region, with an extensive academic research base in genome engineering and a growing biopharmaceutical industry. Continued funding of biomedical research feeds regional demand growth further. As genome engineering research activity grows in academic and commercial applications, reagent suppliers are paying more attention to Argentina and other research institutions in South America.

⮞In March 2025, Abu Dhabi's Department of Health announced the introduction of CASGEVY through the Abu Dhabi Stem Cells Center, marking the first introduction of a CRISPR/Cas9 gene-editing therapy in the UAE. The initiative was intended to provide a new treatment option for eligible patients with sickle cell disease and transfusion-dependent beta-thalassemia.

Market Dynamics:

Growth Drivers: Expanding clinical pipelines and research funding drive CRISPR demand

Increasing clinical pipelines for ex vivo and in vivo gene modification therapies are a primary demand driver, as biopharma companies increasingly advance CRISPR-based programs across hematology, oncology, and cardiovascular indications toward late-stage clinical development and eventual commercialization. Suppliers of reagents, guide RNA libraries and screening services validated against therapeutic development programs are well positioned to benefit from this clinical expansion. Increased demand for manufacturing and service capacity can support expanding biopharmaceutical gene modification pipelines across major consuming regions simultaneously and consistently.

A second driver is sustained academic and government research funding for genome engineering, as universities and government research institutions continue to expand functional genomics and disease model development programs reliant on CRISPR-Cas reagents and screening services. Suppliers offering catalog guide RNA libraries and validated editing kits tailored for academic research budgets are positioned to capture multi-year research funding cycles tied to genomics and precision medicine initiatives, reinforcing demand for reagent capacity sized to support increasingly complex research program requirements across several institutions and regions.

⮞In December 2025, India's Department of Science and Technology announced a public-private partnership between JNCASR and CRISPRBITS to establish the Centre of Excellence for CRISPR Innovation and Translation. The proposed center is intended to connect academic research with applied genome-editing development and support the translation of CRISPR technologies into clinical applications.

Restraints: Delivery limitations and regulatory scrutiny limit CRISPR adoption

Despite the continued development of delivery technology, persistent limitations in delivery technology still pose meaningful restraints as developers continue to face challenges in achieving efficient, tissue-specific in vivo delivery of CRISPR-Cas components without resorting to viral vectors, which carry manufacturing complexity and immunogenicity concerns across therapeutic programs, patient populations and treatment settings. This constraint can lengthen clinical program timelines, even with ongoing investment in reagent and delivery technology, and occasionally necessitates developers to pursue ex vivo editing approaches or defer in vivo program advancement until better delivery platform validation and regulatory clearance are available.

The second restriction is regulatory scrutiny of germline and heritable gene modification applications. Regulatory agencies in major jurisdictions have cautious approval processes that restrict the timelines for commercialization of certain therapeutic and agricultural applications seeking permanent genetic modifications across multiple jurisdictions and regulatory structures. With regulatory review timelines growing, developers are pivoting their focus to somatic cell and ex vivo editing programs as opposed to germline applications. This sometimes necessitates companies to reallocate research funding or delay program advancement when regulatory pathways are unclear within required development timelines.

Opportunities: Base and prime editing advances and agricultural applications widen the addressable market

Advancing base and prime editing technologies represent a significant opportunity, as developers increasingly adopt precision editing approaches that avoid double-strand breaks and offer improved safety profiles for correcting point mutations relevant to inherited disease indications beyond what first-generation nuclease systems could address across multiple therapeutic categories. Suppliers investing early in base and prime editing-compatible reagent and licensing platforms are positioned to establish reference relationships that competitors still reliant on standard Cas9 nuclease systems will need to match over time across multiple program types.

A second opportunity lies in expanding agricultural biotechnology applications, as crop developers increasingly apply CRISPR-Cas systems to trait engineering and disease resistance programs beyond the mature biomedical research categories that historically anchored global consumption for several decades and multiple product cycles, research generations, and funding waves. Suppliers positioned to support this expansion are well placed to capture a growing share of total CRISPR and Cas gene market consumption as more agricultural biotechnology developers adopt gene-edited crop development programs across multiple regions.

⮞In June 2026, the European Union adopted Regulation (EU) 2026/1388 concerning plants obtained through certain new genomic techniques and their products. The regulation establishes a dedicated framework for specified categories of new genomic techniques, creating a more defined regulatory environment for eligible gene-edited plant development and potential agricultural applications of CRISPR technology.

CRISPR and CRISPR-associated (Cas) Genes Market Key Players:

• Thermo Fisher Scientific Inc.

• CRISPR Therapeutics AG

• Intellia Therapeutics, Inc.

• Beam Therapeutics Inc.

• Caribou Biosciences, Inc.

• Takara Bio Inc.

• Merck KGaA

• GenScript Biotech Corporation

• Danaher Corporation

• Editas Medicine, Inc.

• Mammoth Biosciences, Inc.

• Integrated DNA Technologies, Inc.

• Synthego Corporation

• Horizon Discovery Group plc

• Lonza Group AG

• New England Biolabs, Inc.

• Prime Medicine, Inc.

• Agilent Technologies, Inc.

CRISPR and CRISPR-associated (Cas) Genes Market Report Scope: